XNAS
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-06 | Q2 2026 | — | -0.98 | — | $28,000 | — | — | — | — |
| 2025-08-12 | Q1 2026 | — | -1.14 | — | $37,000 | — | +0.00% | +2.63% | +110.67% |
| 2024-11-08 | Q2 2025 |
| -3.12 |
| -1.68 |
| +46.15% |
| $30,000 |
| ✅ Beat |
| — |
| — |
| — |
| 2024-05-31 | Q4 2024 | -5.04 | -3.48 | +30.95% | $29,000 | ✅ Beat | — | — | — |
| 2024-02-08 | Q3 2024 | -6.00 | -4.80 | +20.00% | $5,000 | ✅ Beat | — | — | — |
| 2023-08-10 | Q1 2024 | — | -5.52 | — | $75,000 | — | — | — | — |
| 2023-07-14 | Q4 2023 | — | -10.20 | — | $162,000 | — | — | — | — |
| 2023-02-09 | Q3 2023 | — | -4.44 | — | $131,000 | — | — | — | — |
Showing last 8 quarters.